Factors influencing the therapeutic effect of muscle afferent block for oromandibular dystonia and dyskinesia: Implications for their distinct pathophysiology

International Journal of Oral and Maxillofacial Surgery

Volumn 31, Issue 5, 2002, Pages 499-505

  Yoshida, K ^a   Kaji, R ^b   Shibasaki, H ^a   Iizuka, T ^a  

^a KYOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Dyskinesia; Masticatory muscle; Muscle afferent block; Oromandibular dystonia

Indexed keywords

ALCOHOL; BOTULINUM TOXIN; CENTRAL DEPRESSANT AGENT; LIDOCAINE; LOCAL ANESTHETIC AGENT; PROCAINE; SODIUM CHLORIDE;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CLASSIFICATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; DYSKINESIA; DYSTONIA; EDEMA; FEMALE; HUMAN; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; JAW MOVEMENT; MALE; MANDIBLE; MASTICATION; MASTICATORY MUSCLE; METHODOLOGY; MUSCLE CONTRACTION; MUSCLE SPASM; MUSCLE SPINDLE AFFERENT NERVE; MUSCLE STIFFNESS; NERVE BLOCK; NEUROMUSCULAR BLOCKING; OROFACIAL DYSKINESIA; PAIN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT CODING; PHYSIOLOGY; PREDICTION; SCORING SYSTEM; SIDE EFFECT; SPEECH; STATISTICAL ANALYSIS; STATISTICAL MODEL; SYMPTOM; TONGUE; TONGUE DISEASE; TREATMENT OUTCOME;

EID: 0036787280     PISSN: 09015027     EISSN: None     Source Type: Journal    
DOI: 10.1054/ijom.2002.0291     Document Type: Article

References (27)

1. ARMSTRONG C, BINSTOCK L. The effect of several alcohols on the properties of the squid giant axon. J Gen Physiol 1965: 48: 265-277.
2. BERARDELLI A, ROTHWELL JC, DAY BL, MARSDEN CD. Pathophysiology of blepharospasm and oromandibular dystonia. Brain 1985: 108: 593-608.
3. BERARDELLI A, ROTHWELL JC, HALLETT M, THOMPSON PD, MANFREDI M, MARSDEN CD. The pathophysiology of primary dystonia. Brain 1998: 121: 1195-1212.
4. BLITZER A, BRIN M, GREENE PE, FAHN S. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 1989: 98: 93-97.
5. BRIN MF, BLITZER A, HERMAN S, STEWART C. Therapy with Botulinum Toxin. New York: Marcel Decker 1994: 429-435.
6. FAHN S. Concept and classification of dystonia. Adv Neurol 1988: 50: 1-8.
7. JANKOVIC J, FORD J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983: 13: 402-411.
8. JANKOVIC J, SCHWARTZ K, DONOVAN DT. Botulinum treatment of cranio-cervical dystonia, spasmodic dysphonia, other focal dystonias and hemifacial spasm. J Neurol Neurosurg Psychiatry 1990: 53: 633-639.
9. JANKOVIC J, BRIN MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991: 324: 1186-1194.
10. KAJI R, ROTHWELL JC, KATAYAMA M, IKEDA T, KUBORI T, KOHARA N, et al. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neurol 1995: 38: 155-162.
11. KAJI R, KOHARA N, KATAYAMA M, KUBORI T, MEZAKI T, SHIBASAKI H, et al. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle & Nerve 1995: 18: 234-235.
12. KAJI, R, MEZAKI T. Dystonia and Botulinum Therapy. Tokyo: Shindan-to-Chiryo Sha 1996: 160-171.
13. KAJI R, MURASE N. Sensory function of basal ganglia. Mov Disord 2001: 16: 593-594.
14. KOOLE P, BEENHAKKER F, BRONGERSMA AJ, DE JONGH HJ, BOERING G. A standardized technique for the placement of electrodes in the two heads of the lateral pterygoid muscle. J Craniomandib Pract 1990: 8: 154-162.
15. KUBORI T, KAJI R. Pathophysiology and clinic of idiopathic dystonia. Brain Nerve 1999: 51: 391-402.
16. LILJESTRAND G, MAGNUS R. Über die Wirkung des Novokains auf den normalen und den tetanusstarren Skelettmuskel und über die Entstehung der lokalen Muskelstarre beim Wundstarrkrampf. Pflügers Arch Physiol 1919: 176: 168-208.
17. MATTHEWS P, RUSHWORTH G. The selective effect of procaine on the stretch reflex and tendon jerk of soleus muscle when applied to its nerve. J Physiol 1957: 135: 245-262.
18. MATTHEWS P, RUSHWORTH G. The relative sensitivity of muscle nerve fibers to procaine. J Physiol 1957: 135: 263-269.
19. MEZAKI T, KAJI R, HIROTA N, KOHARA N, KIMURA J. Treatment of spasticity with muscle afferent block. Neurology 1999: 53: 1156-1157.
20. REPORT OF THE THERAPEUTICS AND TECHNOLOGY ASSESSMENT SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY. Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Neurology 1990: 40: 1332-1336.
21. TAN EK, JANKOVIC J. Botulinum toxin A in patients with oromandibular dystonia long-term follow-up. Neurology 1999: 53: 2102-2107.
22. WALSHE F. Observations on the nature of the muscular rigidity of paralysis agitans, and its relationship to tremor. Brain 1924: 47: 159-177.
23. YOSHIDA K, KAJI R, KUBORI T, KOHARA N, IIZUKA T, KIMURA J. Muscle afferent block for the treatment of oromandibular dystonia. Mov Disord 1998: 13: 699-705.
24. YOSHIDA K. Masticatory muscle responses associated with unloading of biting force during food crushing. J Oral Rehabil 1998: 25: 830-837.
25. YOSHIDA K, KAJI R, KUBORI T, KOHARA N, IIZUKA T, KIMURA J. Muskelafferenz-blockierung mittels lokaler Injektion von Lidocain bei Kaumuskelspasmus. Dtsch Zahnärztl Z 1998: 53: 197-199.
26. YOSHIDA K, KAJI R, TAKAGI A, IIZUKA T. Customized EMG needle insertion guide for the muscle afferent block of jaw-deviation and jaw-opening dystonias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999: 88: 664-669.
27. YOSHIDA K, KAJI R, IIZUKA T. Muscle afferent block therapy for oromandibular dystonia. Jpn J Oral Maxillofac Surg 2000: 46: 563-571.